AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.
You may also be interested in...
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event
AstraZeneca plans to broaden its presence across a wide range of developing markets, including small and mid-sized ones, not only to maximize growth but also to smooth out variations in growth rates across countries and regions, top company executives said in a detailed presentation to analysts on March 16
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.